|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...3435363738394041424344...39313932» |
- || Ariely (adebrelimab) / Jiangsu Hengrui Pharma
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial. (Pubmed Central) - Sep 10, 2024
P2
Patients received 4-6 cycles of adebrelimab (20
- | Sylvant (siltuximab) / Jazz, Rituxan (rituximab) / Roche
Journal: Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary. (Pubmed Central) - Sep 10, 2024
In virus-associated diseases, antiretroviral therapy and rituximab are recommended. This report presents our two
- | Libtayo (cemiplimab-rwlc) / Regeneron
Journal: Induction chemotherapy with cemiplimab in a patient with coexistent vulvar cancer and autoimmune disease: A case report. (Pubmed Central) - Sep 10, 2024
We review existing data on neoadjuvant treatment of vulvar cancer and the use of cemiplimab in genital and inguinal squamous cell carcinomas. Ongoing exploration of cemiplimab's efficacy in vulvar cancer and safety in immunosuppressed patients is critical.
- | Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Tivdak (tisotumab vedotin-tftv) / Genmab, Pfizer
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Discrepancy in PD-L1 expression between primary and metastatic tumors in two patients with recurrent cervical cancer. (Pubmed Central) - Sep 10, 2024
She had progression on this regimen and was transitioned to tisotumab vedotin; however, ultimately opted to proceed with hospice secondary to failure to thrive.Case 2A 36-year-old woman with history of an abnormal pap smear in pregnancy and initial biopsy demonstrating endocervical adenocarcinoma, mucinous type...This is the first case report describing these inconsistencies. Etiologies of and outcomes related to the discrepant expression of PD-L1 should be further studied.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. (Pubmed Central) - Sep 10, 2024
The objectives of this multiple technology appraisal were to appraise the clinical effectiveness and cost-effectiveness of lenvatinib plus pembrolizumab versus relevant comparators listed in the final scope issued by the National Institute for Health and Care Excellence: sunitinib, pazopanib, tivozanib, cabozantinib and nivolumab plus ipilimumab...49. See the NIHR Funding and Awards website for further award information.
- || Orencia (abatacept) / BMS
Clinical, Retrospective data, Journal: Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease. (Pubmed Central) - Sep 10, 2024
Abatacept and csDMARDs showed comparable effects on the development and stabilization of RA-ILD. Nevertheless, compared to csDMARDs, abatacept demonstrated a significant improvement in disease activity and led to reduced glucocorticoid use.
- ||| Simulect (basiliximab) / Novartis
Observational data, Retrospective data, Journal, Adverse events, Real-world evidence, Real-world: Safety assessment of basiliximab using real-world adverse event data from the FDA Adverse Event Reporting System Database: A retrospective observational study. (Pubmed Central) - Sep 10, 2024
Although basiliximab offers therapeutic benefits, it carries the risk of several adverse reactions. Clinicians should monitor patients for signs of increased serum creatinine level, fever, cytomegalovirus infection, anaphylactic shock, mitral valve calcification, diastolic dysfunction, pelvic fluid collection, testicular swelling, soft tissue necrosis, muscle necrosis, and other events during clinical use.
- | Kymriah (tisagenlecleucel-T) / Novartis
Journal, Intubation: Transformed follicular lymphoma with laryngeal edema requiring tracheal intubation after tisagenlecleucel treatment: A case report. (Pubmed Central) - Sep 10, 2024
Third, TCZ, as well as DEX, may be inadequate. In such cases, we should recognize L-CRS and manage it early because it may eventually progress to laryngeal edema that requires securing the airway.
- | Doptelet (avatrombopag) / SOBI
Journal: Efficacy and safety of avatrombopag in the treatment of thrombocytopenia after umbilical cord blood transplantation. (Pubmed Central) - Sep 10, 2024
In such cases, we should recognize L-CRS and manage it early because it may eventually progress to laryngeal edema that requires securing the airway. In summary, compared with those in the historical control group, our results indicate that AVA could effectively promote platelet engraftment and recovery after UCBT, especially when used in the early period (?14
- Blenrep (belantamab mafodotin-blmf) / GSK
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin, pomalidomide, dexamethasone vs pomalidomide plus bortezomib, dexamethasone (PVd) in relapsed/refractory multiple myeloma (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_244;
P3
DREAMM-8 demonstrated a statistically significant and clinically meaningful PFS benefit with BPd vs PVd in RRMM with ?1 prior LOT. BPd led to deeper and more durable responses, showed a favorable OS trend, and had a manageable safety profile.
- Ninlaro (ixazomib) / Takeda, iberdomide (CC-220) / BMS
All oral triplet Iberdomide Ixazomib and Dexamethasone in elderly patients with multiple myeloma patients at first relapse: results of the IFM phase 2 study I2D (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_243;
P2
Introduction: The triplet combination daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are to date the standard of care for patients with transplant ineligible (TI) newly diagnosed multiple myeloma (MM)...Iberdomide is a novel oral cereblon E3 ligase modulator (CELMoD) that demonstrated promising activity in MM patients refractory to lenalidomide/pomalidomide... Overall, the oral triplet iberdomide, ixazomib and dexamethasone demonstrated a favorable efficacy / safety profile in elderly MM patients at first relapse, including patients with lenalidomide and daratumumab refractory disease.
- belantamab (GSK2857914) / GSK
Results of a phase 1 clinical trial of belantamab mafadotin (BelMaf) combined with carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma (MM) after one prior line of therapy (LOT) (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_241;
KRd-BelMaf demonstrated deep responses in pts with high-risk features, including HRCGs and R refractory disease. Keratopathy was frequent but manageable with dose delays and reductions.
- Darzalex (daratumumab) / J&J
Frontline Systemic Treatment Outcomes in POEMS Syndrome (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_233;
However, a third of patients were not fit for melphalan ASCT, with inferior depth of response and overall survival. Attainment of CRH and CRV is associated with a significantly lower relapse rate, but late relapses are still seen.
- Sarclisa (isatuximab-irfc) / Sanofi
Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_232;
P3
Compared with the natural history of PETHEMA HRSMM patients (Perez-Persona et al. Blood 2007), treatment with ISA-LEN delayed progression to symptomatic myeloma.
- Talvey (talquetamab-tgvs) / J&J, forimtamig (RG6234) / Roche
Impaired membrane trafficking of GPRC5D mediates resistance to anti-GPRC5D TCE (101 B1-B2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_227;
GPRC5D antigen escape predominantly involve convergence of multiple clones harboring monoallelic chr.12p deletions coupled with GPRC5D mutations. GPRC5D mutations cluster within GPCR conserved motifs involved in protein trafficking and hence prevent its membrane localization.
- Carvykti (ciltacabtagene autoleucel) / J&J
Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_220;
At ~3 years of follow-up, cilta-cel significantly extended OS, reducing the risk of death vs SoC by 45%, and significantly improved quality-of-life measures vs SoC. Collectively, these data continue to support the overall benefit-risk profile of cilta-cel vs SoC in pts with len-refractory MM as early as after first relapse.
- Sarclisa (isatuximab-irfc) / Sanofi
Efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study. (Plenary Hall, Pavilion 3) - Sep 10, 2024 - Abstract #IMW2024IMW_219;
P3
No new safety signals were observed. The ongoing MIDAS study needs further follow-up for final analysis.
- Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study (Plenary Hall, Pavilion 3) - Sep 10, 2024 - Abstract #IMW2024IMW_218;
P3
The ongoing MIDAS study needs further follow-up for final analysis. The addition of DARA to R maint in TE NDMM pts who were MRD pos and anti-CD38 na
- Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study (Plenary Hall, Pavilion 3) - Sep 10, 2024 - Abstract #IMW2024IMW_210;
In pts with TIE or transplant-deferred NDMM, DARA SC + VRd significantly improved PFS vs VRd, reducing the risk of progression or death by 43%. D-VRd significantly increased overall MRD negativity,
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_201;
P1/2
Tal+tec had a safety profile that was similar with each agent as monotherapy. Reponses to tal+tec were consistent across DLs, with robust durability of response at the RP2R.
- Darzalex (daratumumab) / J&J, Talvey (talquetamab-tgvs) / J&J
Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM?2 Study (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_200;
The safety profile was consistent with the known safety profiles of each respective agent. Results support the versatility of tal as a combination partner and warrant further investigation of tal in combination with dara or pom.
- Sarclisa (isatuximab-irfc) / Sanofi
Association of Cardiac biomarkers and Adverse Events with a Carfilzomib-containing Quadruplet in High-risk Newly Diagnosed Multiple Myeloma Patients: Correlative Program of the GMMG-CONCEPT Trial (101 B1-B2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_199;
P2
Elevated levels of NT-proBNP are common in newly diagnosed HR MM pts, but neither the baseline value nor an early change from baseline within the first 3 IND cycles are predictive for CVAEs. In contrast, hsTropI is rarely elevated, but baseline levels below < 2.9 ng/L were negative predictive for the occurrence of CVAE during Isa-KRd quadruplet treatment for high-risk MM.
- Darzalex (daratumumab) / J&J
Liquid chromatography mass spectrometry (LC-MS) for identification of exceptional responders in newly diagnosed multiple myeloma (NDMM). (101 B1-B2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_198;
P2
LC-MS(-) and/or 10-6 MRD(-) patients experience long term disease control. The potential of LC-MS to enhance the prognostic potential of MRD at 10-6 for predicting longer disease control is currently under evaluation in a larger sample set.
- Darzalex (daratumumab) / J&J, iberdomide (CC-220) / BMS
Iberdomide, daratumumab, and dexamethasone (IberDd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_194;
P1/2
Similar results were observed across dose levels. IberDd is being evaluated in an ongoing phase 3 trial in RRMM, and these data further support the evaluation of IBER in NDMM.
- Sarclisa (isatuximab-irfc) / Sanofi
Isatuximab plus lenalidomide and dexamethasone with bortezomib versus isatuximab plus lenalidomide and dexamethasone in newly diagnosed transplant ineligible Multiple Myeloma: The BENEFIT study. (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_193;
Isa-VRd significantly increased MRD end points, including the 18-month negative rate at 10-5 , the primary end point, compared to IsaRd. This study proposes Isa-VRd as a new standard of care for NDMM TI non-frail patients.
- Darzalex (daratumumab) / J&J
Efficacy of Dara-RVD induction therapy in newly diagnosed myeloma (NDMM) patients ?65 years of age (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_192;
DRVd is a highly effective induction regimen demonstrating efficacy in the phase 3 setting, and that we have shown improves upon outcomes in a historical NDMM population treated with RVd in terms of depth of response and PFS benefit. Though benefit was not seen for patients 65-70 years of age in the phase 3 study, our data reflecting real-world clinical practice suggests that these patients can and do benefit from the addition of daratumumab upfront.
- Sarclisa (isatuximab-irfc) / Sanofi
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_191;
P3
Safety was consistent with addition of Isa to VRd. These results support Isa-VRd as a potential new SOC in pts not intended for transplant.
- Darzalex (daratumumab) / J&J
Phase II clinical trial of minimal residual disease response-adapted deferral of transplantation in dysproteinemia (MILESTONE) (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_190;
P2
This study provides the initial feasibility of utilization of post induction MRD in guiding next steps in treatment. This approach is being further explored in the larger ongoing, randomized phase II MASTER-2 clinical trial to see if comparable clinical outcomes are possible without ASCT in those achieving deep response to induction therapy.
- Sarclisa (isatuximab-irfc) / Sanofi
Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_183;
P2
These data from our CONCEPT trial underline the high potency of Isa-KRd to not only induce but also maintain MRD neg remissions in HR NDMM pts irrespective of transplant status. Six years after treatment initiation, more than half of these HR pts are still alive and progression-free.
- Darzalex (daratumumab) / J&J
Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_181;
DARA plus VRd ind/consol and R maint improved PFS and induced higher rates of deep and sustained responses vs VRd ind/consol and R maint across all cytogenetic risk subgroups. These data support D-VRd ind/consol and D-R maint as a new standard of care for TE NDMM, regardless of cytogenetic risk status.
- Darzalex (daratumumab) / J&J
Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update (101 A1-A2, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_180;
P3
Furthermore, receiving DARA maint offers PFS benefit regardless of MRD status. These data support the use of D-VTd ind/conso as a standard of care in TE NDMM pts and demonstrate the additional benefit of DARA monotherapy use during maint for up to 2 y.
- Protocol for Outpatient Administration of Multiple Myeloma Bispecific Antibodies Step-Up Dosing (204A, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_175;
These data support the use of D-VTd ind/conso as a standard of care in TE NDMM pts and demonstrate the additional benefit of DARA monotherapy use during maint for up to 2 y. Introduction: Teclistamab (Tecvayli
- Talvey (talquetamab-tgvs) / J&J
Evaluation of clinical outcomes and toxicities in multiple myeloma patients receiving commercial talquetamab (204A, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_171;
Only 2 patients required treatment delays and no patients discontinued therapy due to oral, skin or nail associated adverse events. Further investigation of the effect of prophylaxis and early intervention for talq-related AEs with optimization of these measures warrant further study in patients receiving treatment with talquetamab.
- Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab-cqyv) / Genmab, J&J
Recommendations for Infection screening and prophylaxis for bispecific antibodies in myeloma: a single center analysis (204A, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_164;
The routine monitoring of CMV allowed for early diagnosis and management resulting in no hospitalizations or death associated with CMV. Under our protocol BsAbs dose frequency was decreased in a treatment response which likely helped with immune reconstitution resulting in fewer infections.
- Talvey (talquetamab-tgvs) / J&J
The real world experience of the incidence, assessment, and management of oral adverse events and weight loss with talquetamab leading to the development of an assessment tool (204A, Convention Center) - Sep 10, 2024 - Abstract #IMW2024IMW_163;
Grading the severity of oral AEs was a limitation in this study due to inconsistencies in documentation across practitioners and a lack of a standardize assessment tool for dysgeusia. Based on symptoms observed in our practice we have developed the Sinai dysgeusia evaluation tool (SiDET) that can identify the impact of dysgeusia and can be applied to evaluate the effectiveness of interventions for dysgeusia and determine if dose adjustments are warranted.
- | Tecentriq (atezolizumab) / Roche
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer. (Pubmed Central) - Sep 9, 2024
For patients with advanced or recurrent EC, the combination of atezolizumab and chemotherapy may not prove cost-effective. However, administering atezolizumab for a limited period of maximum 2 years could improve cost-effectiveness in dMMR EC.
- | Rituxan (rituximab) / Roche
Biomarker, Retrospective data, Journal: Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis. (Pubmed Central) - Sep 9, 2024
Our data support the quantification of MuSK antibodies by flow cytometry. Through a multimodal investigational approach, we showed that total MuSK-IgG levels, MuSK-IgG4 and MuSK-IgG2 levels, and MuSK-IgG affinity may represent promising biomarkers of disease outcomes in MuSK-MG.
- || pazopanib / Generic mfg., sunitinib / Generic mfg.
Clinical, Journal, Head-to-Head: Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. (Pubmed Central) - Sep 9, 2024
45. See the NIHR Funding and Awards website for further award information.
- || Keytruda (pembrolizumab) / Merck (MSD)
P2 data, Journal, Metastases: Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study. (Pubmed Central) - Sep 9, 2024
P2
Trial registration number ClinicalTrials.gov (No. NCT03322267).
- || Rituxan (rituximab) / Roche
Review, Journal: The efficacy of rituximab in the treatment of IgA vasculitis nephritis. (Pubmed Central) - Sep 9, 2024
Interestingly, 76.9% (10/13) of IgAVN child patients achieved complete remission when compared with 32.1% (9/28) of adult patients (P?=?0.017). In summary, our results support the benefit of RTX therapy in IgAVN patients, especially children subjects.
- || Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review. (Pubmed Central) - Sep 9, 2024
MAbs used in MS immunotherapy have shown to induce secondary autoimmune disorders including endocrine complications, which have been reported in many case reports. It is recommended to use these agents with caution and monitor patients for symptoms of the aforementioned conditions.
- | Rixathon (rituximab biosimilar) / Kyowa Kirin, Sandoz, Rituxan (rituximab) / Roche
Retrospective data, Journal: Safety of Rituximab biosimilar (Riximyo (Pubmed Central) - Sep 9, 2024
There was no statistical significant differences for any safety outcomes examined. Switching therapy for patients receiving rituximab does not lead to poorer safety outcomes.
- | Opdivo (nivolumab) / BMS
Retrospective data, Journal, Metastases: Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. (Pubmed Central) - Sep 9, 2024
Switching therapy for patients receiving rituximab does not lead to poorer safety outcomes. Adding-on nivolumab was associated with improved OS in patients with advanced PDAC who achieved disease control following chemotherapy.
- || Verzenio (abemaciclib) / Eli Lilly
Retrospective data, Review, Journal, Combination therapy, Metastases: Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Sep 9, 2024
Abemaciclib, particularly in combination with fulvestrant, emerges as an effective therapeutic option for HR+/HER2- advanced or metastatic breast cancer, improving PFS and OS. The higher toxicity profile warrants cautious use, especially in treatment-naive patients.
- || Darzalex (daratumumab) / J&J
Clinical, Retrospective data, Review, Journal: Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis. (Pubmed Central) - Sep 9, 2024
Our results indicate that MM patients with RI could benefit from a daratumumab-added regimen regardless of MM status. Additional high-quality RCTs are still warranted to confirm our findings.
- | Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Biomarker, Journal: Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration. (Pubmed Central) - Sep 9, 2024
Additional high-quality RCTs are still warranted to confirm our findings. Our findings allow better stratification of CAR-Tx candidates and stress the need for a proactive approach (earlier restaging, intervention after partial remission achievement).
- | Rituxan (rituximab) / Roche
Journal: Abdominal obstruction revealing colonic lymphoma: a case report (Pubmed Central) - Sep 9, 2024
Treatment is based on surgery and chemotherapy. We here report a case of diffuse colonic large B-cell lymphoma revealed by occlusion and diagnosed based on the examination of surgical specimen in a 64-year-old man who was in complete remission after six courses of R-CHOP.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Surgery, Metastases: The Role of Surgery in Metastatic Renal Cell Carcinoma in 2024. (Pubmed Central) - Sep 9, 2024
In summary, CN brings survival benefits to well-selected good-to-intermediate-risk mRCC patients. Individualized and multidisciplinary care is pivotal.
- | Retrospective data, Journal, Metastases: First?line endocrine therapy for hormone receptor positive and HER?2 negative metastatic breast cancer: A Bayesian network meta?analysis. (Pubmed Central) - Sep 9, 2024
Considering the effect on OS and PFS together with adverse reactions, safety, medical compliance and route of administration, PalboAI was found to be the optimal treatment for HR+/HER2-mBC. However, additional head-to-head clinical trials are warranted to confirm these findings.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Treatment outcomes of vulvar and vaginal melanoma at an NCCN institution between 1993 and 2021. (Pubmed Central) - Sep 9, 2024
Seven patients experienced complete responses to therapy after recurrence of whom five received immune checkpoint inhibitors. Although survival is not improved as in cutaneous melanomas by immune checkpoint inhibitors, signal continues for the use of immune checkpoint inhibitors in gynecologic melanomas.